Cancer test kit SHIELDING™ ULTRA

oncologyfor precision medicineblood

Early stage cancer patients can attain durable disease-free survival after curative surgery. However, there are still a substantial number of patients suffering from local recurrence or distant metastasis. Minimal Residual Disease (MRD) refers to the small amount of cancer cells left in the body after treatment. These cells have the potential to come back and cause relapse in patients, increasing the risks of recurrence. Thus it is important to monitor and evaluate the levels of MRD throughout patient‘s full course of treatment to improve overall outcomes. A full-course perioperative MRD monitoring program for solid tumors Customized tracking panel of hotspot regions in 2365 cancer-related genes to cover as many patients with solid tumors as possible Sampling at multiple critical time points during the full disease course Ultra-high sensitivity for ctDNA dynamic monitoring using ATG-Seq™ technology WHO IS IT FOR Patients with resectable stage I-III solid tumors SAMPLE TYPES Tumor tissue (FFPE block/slides, fresh or frozen tissue) Peripheral blood Shielding™ ULTRA Report Comprehensive genomic profiling for guiding the selection of neoadjuvant/adjuvant therapy, and targeted drugs for subsequent lines of treatment Monitoring the efficacy of neoadjuvant therapy and predicting the risk of recurrence post-surgery before undergoing surgery Post-surgery MRD detection for predicting risk of recurrence and facilitating adjuvant therapy decision-making Dynamic monitoring the efficacy of adjuvant therapy and recurrence for early intervention